Qujing

Researchers are studying the gut microbiome in people with several serious chronic diseases in China, including various cancers, hypertension, epilepsy, and kidney disease. The study aims to better understand the differences and similarities in gut microbiome patterns linked to these diseases and different regions, and how these patterns affect microbiome-based diagnostic tests. This work is important because past research has shown links between microbial imbalances and disease, but variability between studies has made it hard to draw clear conclusions. This observational study will recruit 500 patients diagnosed with each target disease and 500 healthy control participants matched by age and sex. Researchers will collect detailed information about participants' demographics, lifestyle, diet, medications, and health status. Biological samples including feces, saliva, urine, and blood will be collected for analysis. There is no active treatment or intervention; the study focuses on characterizing the microbiome and related health data. Participants will undergo assessments of their medical history and lifestyle, with sample collections to analyze microbiome and biochemical markers. Researchers will measure the baseline microbiome to identify disease-associated signatures. The study requires participants to be aged 18 to 75 and to have lived in the hospital's province for at least three years. Safety monitoring is observational, with no study treatments given. The total participant involvement includes data and sample collection for cross-sectional analysis.

This registry study is designed to monitor the safety and effectiveness of Medtronic Neurovascular products used in treating intracranial aneurysms and acute ischemic stroke. It is an observational, prospective, multi-center, single-arm study aiming to provide ongoing evaluation and periodic reports of these market-released devices. The study includes patients treated with specific Medtronic products under the Product Surveillance Registry platform. Participants will receive treatments involving the embolization of aneurysms or revascularization of intracranial blood vessels using Medtronic devices. The study collects data on patients who are treated or intended to be treated with these eligible products. Enrollment occurs within the treatment window, and patients may be followed according to the registry's protocol to gather safety and effectiveness information. During the study, participants will undergo assessments to measure the clinical success of treatment, defined as complete occlusion of the target aneurysm without retreatment or significant artery narrowing at one year, as well as functional independence measured by a modified Rankin Scale score at 90 days. Safety monitoring and follow-up are conducted to ensure long-term observation of outcomes. The study includes adult patients, and participation duration depends on follow-up schedules for the treated condition.

Researchers are studying the effects of normobaric oxygen (NBO) therapy on patients who have experienced an acute ischemic stroke (AIS) and are transferred for endovascular thrombectomy (EVT). The goal is to assess the safety and effectiveness of NBO in improving functional outcomes three months after stroke. Stroke is a major cause of death and disability worldwide, and while treatments like mechanical thrombectomy can improve blood flow, less than half of patients with large vessel occlusion achieve good recovery. NBO offers potential brain protection by improving oxygen delivery to affected areas and reducing damage through multiple mechanisms. Participants will receive either inhaled 100% oxygen (NBO) or best medical care without NBO. The study focuses on patients transferred for EVT who meet specific stroke severity and imaging criteria. NBO treatment is delivered through oxygen inhalation, aiming to increase oxygen availability to the brain before reperfusion. The study is conducted in a Phase 3 setting and compares outcomes between those receiving NBO and those receiving standard care. During the study, participants will be monitored for disability levels using the modified Rankin scale at 90 days and one year after treatment. Assessments include neurological exams and imaging to confirm stroke details and severity. Researchers will also track safety and functional outcomes to evaluate the impact of NBO therapy. Participants are followed for at least three months after randomization to observe recovery and potential benefits.

Researchers are investigating the effectiveness and safety of PM8002, a bispecific antibody targeting PD-L1 and VEGF, combined with Paclitaxel as a second-line treatment for small cell lung cancer (SCLC). This phase III, open-label, randomized study compares this combination to standard chemotherapy options, including Topotecan or Paclitaxel, in patients whose cancer has progressed after first-line platinum-containing chemotherapy. The study aims to improve outcomes for patients with advanced SCLC. Participants will be randomly assigned to receive either PM8002 with Paclitaxel or the investigator's choice of chemotherapy (Topotecan or Paclitaxel). Paclitaxel is given as a 175 mg/m2 intravenous infusion on Day 1 every three weeks, while Topotecan is administered as 1.25 mg/m2 per day via intravenous infusion on Days 1 through 5 every three weeks. PM8002 dosing follows a predefined schedule. The study involves multiple centers and evaluates these treatments as second-line therapy. During the study, participants will undergo regular assessments to monitor overall survival for up to approximately 32 months from the first patient enrolled. Researchers will evaluate safety and treatment effects through clinical examinations, tumor measurements following RECIST v1.1 criteria, and tests of organ function. The study also includes monitoring for adverse events and ensures participants have a life expectancy of at least 12 weeks, adequate organ function, and an ECOG performance score of 0 or 1 to participate.

Researchers are evaluating the effectiveness and safety of Inpegsomatropin injection compared with recombinant human growth hormone (rhGH) in children with short stature who were born small for gestational age (SGA). This is a Phase III, multicenter, randomized, open-label trial involving 141 children. Participants will be grouped by gender and age, then randomly assigned to one of three groups for treatment. The study includes a screening period of up to 12 weeks, followed by a 52-week treatment phase, and a 5-week post-treatment follow-up. The study compares two doses of Inpegsomatropin injection given once weekly by subcutaneous injection—140 mcg/kg/week and 280 mcg/kg/week—against daily subcutaneous recombinant human growth hormone injection at 0.033 mg/kg/day, all administered for 52 weeks. Participants will be randomly assigned to receive one of these treatment regimens. The trial aims to assess the impact of these treatments on growth velocity and safety in the target population. During the study, children will undergo regular assessments including monitoring of growth velocity measured at 52 weeks. Safety and efficacy will be thoroughly evaluated throughout the treatment and follow-up periods. The study involves close observation of participants' health and growth development to determine the effects of the treatments compared. The total participation duration includes screening, one year of treatment, and a short safety follow-up period.